Diabetes. Type 2 diabetes mellitus
Conditions
Interventions
Intervention 1: Intervention group: Patients in this group receive a 500 mg capsule of herbal drug twice a day after breakfast.The herbal drug capsule contains mixture of mentioned herbal extract powd
Sponsors
Iranian academic center for education culture and research
Eligibility
Sex/Gender
All
Age
40 Years to 60 Years
Inclusion criteria
Inclusion criteria: Patients with mild to moderate type 2 diabetes 40 to 60 years old Have diabetes for at least two years Under treatment with a maximum daily dose of 1000 mg metformin and 10 mg glibenclamide Fasting blood glucose levels between 130 to 170 mg/dL Glycosylated hemoglobin between 7.5 to 8.5%
Exclusion criteria
Exclusion criteria: Patients with diabetic foot ulcer, gangrene, or any severe illness Painful diabetic neuropathy and depressed patients Smokers and alcoholic patients Patients who tend to change their exercise program or diet
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fasting blood glucose. Timepoint: At starting of the study and after 3 months. Method of measurement: Blood glucose level will be determined in laboratory by commercial standard kit.;Glycosylated hemoglobin. Timepoint: At starting of the study and after 3 months. Method of measurement: Glycosylated hemoglobin will be determined in laboratory by commercial standard kit. | — |
Secondary
| Measure | Time frame |
|---|---|
| Triglyceride. Timepoint: At starting of the study and after 3 months. Method of measurement: Blood triglyceride level will be determined in laboratory by commercially available kit.;Cholesterol. Timepoint: At starting of the study and after 3 months. Method of measurement: Blood cholesterol level will be determined in laboratory by commercially available kit.;Low-density lipoprotein. Timepoint: At starting of the study and after 3 months. Method of measurement: Blood low-density lipoprotein level will be determined in laboratory by commercially available kit.;High-density lipoprotein. Timepoint: At starting of the study and after 3 months. Method of measurement: Blood High-density lipoprotein level will be determined in laboratory by commercially available kit.;Aspartate aminotransferase. Timepoint: At starting of the study and after 3 months. Method of measurement: Blood aspartate aminotransferase level will be determined in laboratory by commercially available kit.;Alanine aminotransferase. Timepoint: At starting of the study and after 3 months. Method of measurement: Blood alanine aminotransferase level will be determined in laboratory by commercially available kit.;Blood urea nitrogen. Timepoint: At starting of the study and after 3 months. Method of measurement: Blood blood urea nitrogen level will be determined in laboratory by commercially available kit.;Creatinine. Timepoint: At starting of the study and after 3 months. Method of measurement: Blood creatinine level will be determined in laboratory by commercially available kit.;Alkalin phosphatase. Timepoint: At starting of the study and after 3 months. Method of measurement: Blood Alkalin phosphatase level will be determined in laboratory by commercially available kit. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHasan Fallah Huseini
Iranian academic center for education culture and research
Outcome results
None listed